Extrinsic Protein Tyrosine Phosphatase Non-Receptor 22 Signals Contribute to CD8 T Cell Exhaustion and Promote Persistence of Chronic Lymphocytic Choriomeningitis Virus Infection

Tatiana Jofra1, Giuseppe Galvani1, Mirela Kuka1, Roberta Di Fonte1, Bechara G. Mfarrej1, Matteo Iannacone1, Shahram Salek-Ardakani2, Manuela Battaglia1 and Georgia Fousteri1*

1 Division of Immunology, Transplantation and Infectious Diseases (DITID), Diabetes Research Institute (DRI) IRCCS San Raffaele Scientific Institute, Milan, Italy. 2 Department of Pathology, Immunology and Laboratory Medicine, University of Florida, Gainesville, FL, United States.

A genetic variant of the protein tyrosine phosphatase non-receptor 22 (PTPN22) is associated with a wide range of autoimmune diseases; however, the reasons behind its prevalence in the general population remain not completely understood. Recent evidence highlights an important role of autoimmune susceptibility genetic variants in conferring resistance against certain pathogens. In this study, we examined the role of PTPN22 in persistent infection in mice lacking PTPN22 infected with lymphocytic choriomeningitis virus clone 13. We found that lack of PTPN22 in mice resulted in viral clearance 30 days after infection, which was reflected in their reduced weight loss and overall improved health. PTPN22−/− mice exhibited enhanced virus-specific CD8 and CD4 T cell numbers and functionality and reduced exhausted phenotype. Moreover, mixed bone marrow chimera studies demonstrated no differences in virus-specific CD8 T cell accumulation and function between the PTPN22+/+ and PTPN22−/− compartments, showing that the effects of PTPN22 on CD8 T cells are T cell-extrinsic. Together, these findings identify a CD8 T cell-extrinsic role for PTPN22 in weakening early CD8 T cell responses to collectively promote persistence of a chronic viral infection.

Keywords: protein tyrosine phosphatase non-receptor 22, persistent viral infection, T cell exhaustion, lymphocytic choriomeningitis virus clone 13, genetic predisposition

Abbreviations: PTPN22, protein tyrosine phosphatase non-receptor 22; LCMV Arm, lymphocytic choriomeningitis virus Armstrong; LCMV Cl13, lymphocytic choriomeningitis virus clone 13; CTL, cytotoxic lymphocyte; DMR, dextramer; ICCS, intracellular cytokine staining; Th, T follicular helper; GC, germinal center; DC, dendritic cell; dpi, days post infection; spf, specific pathogen free.
INTRODUCTION

The autoimmune predisposing allele of protein tyrosine phosphatase non-receptor 22 (PTPN22) has attracted a lot of attention due to its association with several autoimmune diseases such as type 1 diabetes and rheumatoid arthritis (1, 2). Studies in mouse models of autoimmunity have shown that PTPN22 can have an inhibitory or accelerating influence on disease progression that is dependent on the genetic background, the overall immunological context, and importantly, the type of effect on the disease-driving or regulatory T cell subset (3). PTPN22 plays a dual role in the immune system; on the one hand, it dampens effector T cell responses, but on the other hand, it promotes the activation and pro-inflammatory cytokine production by innate immune cells (4). Likely, this dual role of Ptpn22 in innate and adaptive immunity is responsible for the confounding results observed in the different disease models studied so far.

It has been puzzling how a gene that has such a strong impact on autoimmunity would show high prevalence in the general population. Recent evidence suggests that many of the genes conferring susceptibility to autoimmunity control immunoregulatory factors that are implicated in host–pathogen interactions (5). Thus, it is possible that the Ptpn22 autoimmune predisposing allele provides an immunological advantage. Interestingly, several of the phenotypes described in mice knocked-in with the human autoimmune Ptpn22 allele are similar to those seen in Ptpn22-deficient mice (6–8). Recent studies addressing the role of Ptpn22 in antiviral immunity either by studying PTPN22−/− mice or cells from carriers of the autoimmune-associated variant showed a clear link between PTPN22 and effective responses to acute viral infection (9). In the setting of acute lymphocytic choriomeningitis virus Armstrong (LCMV Arm) infection, it has been shown that mice deficient for PTPN22 produce reduced number of LCMV-specific cytotoxic lymphocytes (CTLs) due to a weakened innate immune response and T cell-intrinsic defects in response to type I IFNs (10–12). However, pathogen control is largely unaltered, suggesting that the role of PTPN22 in the setting of acute LCMV Arm infection is largely dispensable (11).

The dual function of PTPN22 in innate and adaptive immunity might be reflected in the T cell functional or developmental phenomena that occur during viral persistence. Hence, we tested the biological relevance of PTPN22 in the lymphocytic choriomeningitis virus clone 13 (LCMV Cl13) viral infection system, where two amino acid substitutions in the virus genome cause persistent infection for more than 3 months, leading to antiviral immunity either by studying PTPN22−/− mice or cells from carriers of the autoimmune-associated variant showed a clear link between PTPN22 and effective responses to acute viral infection (9). In the setting of acute lymphocytic choriomeningitis virus Armstrong (LCMV Arm) infection, it has been shown that mice deficient for PTPN22 produce reduced number of LCMV-specific cytotoxic lymphocytes (CTLs) due to a weakened innate immune response and T cell-intrinsic defects in response to type I IFNs (10–12). However, pathogen control is largely unaltered, suggesting that the role of PTPN22 in the setting of acute LCMV Arm infection is largely dispensable (11).

The dual function of PTPN22 in innate and adaptive immunity might be reflected in the T cell functional or developmental phenomena that occur during viral persistence. Hence, we tested the biological relevance of PTPN22 in the lymphocytic choriomeningitis virus clone 13 (LCMV Cl13) viral infection system, where two amino acid substitutions in the virus genome cause persistent infection for more than 3 months, leading to antiviral CD4 and CD8 T cells that are physically deleted or persist in a “non-functional” state and characterized by the inability to produce effector cytokines (exhausted T cells) (13–16). We show that mice deficient for PTPN22 are able to control the virus 30 days after infection, show reduced weight loss, and generate higher numbers of LCMV-specific CTLs and CD4 T cells with heightened function. To address whether the increased exhaustion of T cells in PTPN22−/− mice was due to direct effects of PTPN22 on T cells or on another cell type that changes viral load and therefore the degree of exhaustion, we performed mixed bone marrow chimeras. These experiments showed that the effects of PTPN22 on CD8 T cells are largely cell-extrinsic. Taken together, our studies provide evidence for a critical role for PTPN22 in suppressing the initial priming and functional differentiation of CD8 T cells to promote viral persistence.

MATERIALS AND METHODS

Mice, Virus, and Infection

Wild-type and Ptpn22-deficient (PTPN22−/−) littermate mice were used (6). Mice were housed under specific pathogen free conditions in compliance with the guidelines of the San Raffaele Institutional Animal Care and Use Committee (approved protocol #677). LCMV Cl13 plaque-purified was prepared by a single passage on BHK-21 cells and used throughout the experiments. A single dose of 2 × 105 PFU i.v. was used to induce chronic infection as previously described (17).

Virus Titration

Lymphocytic choriomeningitis virus titers of infected spleens were determined in a virus plaque assay as previously described (11). Tissue samples (frozen at −80°C) were thawed, homogenized in MEM, and added to the MC57 cells in fivefold dilution steps. 4 h later, methylenetoluidine (Methocel, Sigma, MO, USA) was used as a secondary antibody, and a color reaction was performed using 3,3′-diaminobenzidine tablets (SIGMAFAST™ Sigma, MO, USA).

Mixed Bone Marrow Chimeras

PTPN22+/+ (CD45.1−CD45.2+):PTPN22−/− (CD45.1−CD45.2−) mixed bone marrow chimeras were generated by i.v. reconstituting lethally irradiated C57BL/6 mice (CD45.1+CD45.2+) with a 1:1 mixture of bone marrow cells for a total of 10 × 106 cells. For control, PTPN22−/+ (CD45.1−CD45.2+) (littermates of PTPN22−/− mice):PTPN22−/− (CD45.1+CD45.2−) mixed bone marrow chimeras were generated. Recipients were treated with gentamycin 400 mg/l starting 1 week prior to reconstitution until 2 weeks after reconstitution.

Flow Cytometry

Following an Fc (anti-CD16/32) blocking step, cells were stained with anti-CD3, -CD4, -CD8, -CD45.1, -CD45.2, -CD25, -CD62L, -CD44, -CD127, -KLRG1, -CD19, -B220, -PD-1, -LAG-3, -LFA-1, -SLAM, -CXCR5, -ICOS, -IgD, -CD138, and -GL7 mAbs (Miltenyi, BD, Biolegend and eBioscience), and then intracellularly with anti-T-BET and -IRF4 mAb using the FOXP3 Fixation/Permeabilization kit (eBioscience). D5GP35–41 and D5NP396–404 MHC class I dextramers (DMRs) were used (Immudex) as described previously (11). Following in vitro stimulation for 3 h with 1 µg/ml of the class I peptides (GP35–41, NP396–404, GP276–286, and NP295–302) and 4 h with 2 µg/ml of the class II epitope (GP61–70) in the presence of brefeldin A, cells were stained for IFN-γ,
TNS, and IL-2 using the Cytofix/Cytoperm kit (BD) according to manufacturer's instructions. All samples were acquired on a FACSCanto flow cytometer (BD).

**Statistical Analysis**

Comparisons between groups were performed Kruskal–Wallis analysis followed by Dunn's posttest between groups without correction. Differences between PTPN22+/+ and PTPN22−/− were also analyzed with the Mann–Whitney test. For weight loss, the log rank test was applied. In all cases, the Prism software (GraphPad, USA) was used. All error bars indicate SEM. Asterisks in the graphs indicate significant p values as follows: *p < 0.05, **p < 0.01, ***p < 0.001.

**RESULTS**

**Improved Viral Control in the Absence of PTPN22**

To analyze the effect of PTPN22 on T cell exhaustion and virus clearance in chronic LCMV CI13 infection, we infected PTPN22+/+ and PTPN22−/− mice with 2 × 10⁶ PFU LCMV CI13. Because LCMV CI13 infection causes severe immunopathology characterized by extensive weight loss that in some cases leads to severe comorbidity (18), we monitored weight loss over time. Interestingly, PTPN22−/− mice had a much healthier appearance that was reflected in their reduced weight loss (Figure 1A). Next, we analyzed whether PTPN22 affects the capability of mice to control viral replication. We quantified viral titers in the spleen at various time points after infection. Strikingly, PTPN22−/− mice were characterized by lower viral titers as early as 3 and 8 days post infection (dpi) (Figure 1B). This difference was even more remarkable by 30 dpi, when viral titers dropped below the detection limit in the spleens of PTPN22−/− mice, while PTPN22+/+ mice displayed consistently higher viral titers (Figure 1C).

**Increased Quantity and Quality of LCMV-Specific CTLs in the Absence of PTPN22**

Because LCMV CI13-infected mice experience severe lymphopenia caused by immunopathology, we analyzed T and B cell populations 8, 15, and 30 dpi in PTPN22+/+ and PTPN22−/− animals. We found that the absence of PTPN22 did not alter LCMV CI13-induced lymphopenia (data not shown). Next, we analyzed the impact of PTPN22 on LCMV-specific T cell responses. Using MHC class I-restricted DMRs, we detected similar frequency and number of LCMV-specific (GP₃₃–₄₁ and NP₉₆–₁₀₄) CD8 T cells in PTPN22−/− and PTPN22+/+ mice 8 dpi (Figures 2A,B). Whereas the proportion of terminal effector (CD127− KLRG1+) was similar within LCMV-specific CTLs, memory precursor cells (CD127+ KLRG1−) were increased in PTPN22−/−–infected animals (Figures 2C,D). Frequency and number of LCMV-specific CTLs was higher in PTPN22−/− mice 30 dpi (Figures 2E,F), showing that in PTPN22−/− mice where the virus is cleared faster, cells could differentiate earlier into memory cells. The expression levels (geometric mean) of PD-1 and LAG-3, two molecules that are highly upregulated on exhausted T cells (19), were considerably lower on LCMV-specific CTLs from PTPN22−/− mice 30 dpi (Figures 2G,H).

The magnitude and functionality of the anti-LCMV CD8 T cell responses were then assessed by epitope-specific intracellular cytokine staining. By analyzing the expression of key effector and stimulatory cytokines, IFN-γ, TNF, and IL-2 (19), we found greater numbers of cytokine producing cells in PTPN22−/− animals in response to class I epitopes as compared to controls at 8 and 30 dpi (Figure 3). We characterized the expression of LFA-1, T-BET, and IRF4, whose expression levels associate with effector function (20–22). No differences were observed among PTPN22+/+ and PTPN22−/− central memory-like (CD44+CD62L−) and effector memory-like (CD44+CD62L+) polyfunctional CTLs 8 dpi (Figure 4). Together, these findings reveal an important role for PTPN22 in the CD8 T cell response and control of a chronic LCMV infection.

**PTPN22 Controls Antiviral CD4 T Cell Responses to LCMV CI13**

CD4 T cells and cytokines derived from these cells, such as IFN-γ and TNF, have pleiotropic antiviral effects and are essential for the control of viremia in LCMV CI13 infection (23, 24). Consequently, we analyzed the effect of PTPN22 on antiviral CD4 T cell responses in the LCMV CI13 system. The differences in pro-inflammatory
cytokine production were even more pronounced in the antiviral CD4 T cell compartment, where we detected significantly higher frequency of IFN-γ, TNF, and IL-2-producing CD4 T cells in the absence of PTPN22 8 and 30 dpi, whereas that of plasma cells was lower in PTPN22−/− mice (Figures 6D,E), whereas that of plasma cells was lower in PTPN22−/− mice (Figures 6F,G). Together, these findings clearly show that PTPN22 inhibits pro-inflammatory virus-specific CD4 T cell responses during LCMV CI13 infection.

PTPN22 Promotes CTL Exhaustion through CD8 T Cell-Extrinsic Effects

The action of PTPN22 on T cells could be cell-autonomous or extrinsic, since PTPN22 has a direct role in T cells and in early innate pro-inflammatory responses (6, 10). To determine if CD8 T cell-intrinsic effects were responsible for improved viral titers in LCMV CI13-infected mice, we performed mixed bone marrow chimeras. If the effect of PTPN22 on CD8 T cell exhaustion is T cell-intrinsic, then PTPN22−/− CD8 T cells would be equally affected and their number and exhaustion phenotype would be similar. Instead, if the effect of PTPN22 is T cell-extrinsic, then PTPN22−/− CD8 T cells would be at a competitive advantage and will be less exhausted. We reconstituted lethally irradiated C57BL/6 mice (CD45.1+CD45.2−) with 1:1 mixture of CD45.1+CD45.2− PTPN22−/−;CD45.1−CD45.2+ PTPN22−/− bone marrow cells (Figure 7A). For control, we used 1:1 mixture of CD45.1+CD45.2− PTPN22−/−;CD45.1−CD45.2+ PTPN22−/− bone marrow cells. Donors were traced by congenic markers and the CD45.1+CD45.2−:CD45.1−CD45.2+ ratio in peripheral blood was 1:1 and similar proportions of CD4 and CD8 T cells could be detected prior to infection (Figure 7B).
Eight days p.i. similar number of total circulating CD8 T cells between PTPN22^{+/+} and PTPN22^{-/-} lymphocytes were observed (Figure 7C). Among CD8 T cells, the proportion of DMR^+ LCMV-specific CTLs was also similar (Figure 7D). Additionally, LCMV-specific CTLs displayed similar levels of the inhibitory receptor PD-1 (Figure 7E). At 30 dpi, there was still no significant effect of PTPN22 on total CD8 splenocytes, DMR^+ CD8 T cells and PD-1 expression levels (Figures 7F–H). The frequency of cytokine-producing CTLs was also similar in the two PTPN22 compartments (Figure 7I), a finding which is in line with their evenly exhausted phenotype. Results in the control PTPN22^{+/+}:PTPN22^{+/+} mixed bone marrow chimeras were similar (data not shown). Taken together, these results demonstrate that when PTPN22^{-/-} CTLs are found in the same environment as PTPN22^{+/+} CTLs are equally exhausted. Thus, the effect of PTPN22 on CD8 T cell exhaustion is CD8 T cell-extrinsic.

We additionally analyzed the CD4 compartment in the bone marrow chimera experiments. At 30 dpi, there was a significant effect of PTPN22 on total CD4 T cells, with more CD4 T cells in the PTPN22^{-/-} compartment (Figure 7J). Among CD4 T cells, there was a two-fold increase in PTPN22^{-/-} Tfh cells and Th1 cells (Figure 7J). However, this increase was due to the accumulation of the CD4 compartment and not due to a differentiation advantage of PTPN22^{-/-} CD4 T cells into Tfh (SLAM^+CXCR5^+) or Th1 (SLAM^+CXCR5^-), since the frequency of PTPN22^{+/+} and PTPN22^{-/-} Tfh and Th1 within CD4s was similar (Figure 7K). Additionally, PD-1 and ICOS levels and cytokine production were similar (Figures 7L,M). These data demonstrate that under
PTPN22 in Chronic Infection

**DISCUSSION**

The human variant of PTPN22 R619W is strongly associated with autoimmunity. While there have been a number of studies addressing the role of PTPN22 in different models of autoimmunity (3), relatively less has been done to address the role of PTPN22 in immunity against pathogens. PTPN22 is of particular interest in this regard because it plays a significant role in antigen receptor signaling in T and B cells [reviewed in Ref. (4)], as well as in TLR signaling in innate cells (10). During chronic viral infection, persistent antigen presentation results in functional exhaustion of T cell responses, characterized by upregulation of inhibitory molecules and a progressive loss of effector functions (29). Here, by studying the effect of PTPN22 in the LCMV CI13 persistent infection system, we show that PTPN22−/− mice show accelerated viral clearance of LCMV CI13 infection by producing higher numbers of viral-specific CD4 and CD8 T lymphocytes with heightened function (30). PTPN22 deficiency did not result in a change in the number of GP33–41-specific LCMV-specific CTLs 8 dpi. However, at later time points (in our case 30 dpi), there was almost a twofold increase in the number of PTPN22−/− mice compared to WT mice when CD4 T cells and effector differentiation of CD4 and CD8 T cells.

Recently, a similar study was published by Professor Sherman’s group (30). Similar to ours, Maine et al. found that PTPN22-deficient mice show accelerated viral clearance of LCMV CI13 infection by producing higher numbers of viral-specific CD4 and CD8 T lymphocytes with heightened function (30). PTPN22 deficiency did not result in a change in the number of GP33–41-specific LCMV-specific CTLs 8 dpi. However, at later time points (in our case 30 dpi), there was almost a twofold increase in the number of PTPN22−/− mice compared to WT mice when CD4 T cells and effector differentiation of CD4 and CD8 T cells.

Maine et al. identified an important role of the augmented CD4 responses in viral protection. They showed no protection from viral persistence in PTPN22−/− mice when CD4 T cells showed an expansion advantage over WT CD4 T cells but have similar potential in differentiating into Tfh and Th1. Hence, PTPN22 controls CD4 accumulation during LCMV CI13 infection via T cell-intrinsic mechanisms.

**FIGURE 1** | Similar levels of LFA-1, T-BET, and IRF4 on CD8 T cells in the absence of protein tyrosine phosphatase non-receptor 22 (PTPN22). PTPN22+/+ (black circles) and PTPN22−/− (white circles) mice were infected as in Figure 1. (A,B) LFA-1, T-BET, and IRF4 levels were determined in PTPN22+/+ and PTPN22−/− central memory (CD44+CD62L+) (A) and effector memory (CD44+CD62L−) (B) polyclonal CD8 cells 8 days post infection (dpi). Representative histogram overlays show one mouse per group. Data are derived from a total of three independent experiments, one representative experiment is shown per graph.

**FIGURE 5** | PTPN22−/− mice have improved antiviral CD4 T responses following lymphocytic choriomeningitis virus clone 13 infection. PTPN22−/− (black circles) and PTPN22−/− (white circles) mice were infected as in Figure 1. (A–D) Production of IFN-γ and TNF by GP33–41-specific CD4 T cells was performed by intracellular cytokine staining at 8 (A,B) and 30 days post infection (dpi) (C,D). (E) LFA-1, T-BET, and IRF4 levels were determined in PTPN22+/+ and PTPN22−/− CD44+ CD8 cells 8 dpi.
were depleted (30). Our bone marrow chimera studies demonstrated a critical role for PTPN22 in postpriming accumulation of CD4 T cells. Interestingly, some expansion advantage of CD4 T cells was also seen by Professor Sherman’s group using class II-restricted TCR transgenic T cells and adoptive transfer experiments (30). In their studies, Maine et al. also found that the resulting CD4 T cells produced higher levels of effector cytokines. As suggested by Maine et al., PTPN22 expression in CD4 T cells may promote the exhaustion phenotype of LCMV-specific CTLs.

We additionally analyzed the expression levels of T-BET, LFA-1, and IRF4 in CD4 and CD8 T cells. Whereas no differences were observed in CD8 T cells, T-BET expression levels were higher on CD4+CD44+ T cells from PTPN22−/− mice 8 dpi, suggesting that PTPN22 dampens the pro-inflammatory function of CD4 T cells via T-BET downmodulation. Neutralizing antibodies against LCMV C113 appear at around 90 days after infection and are essential for viral clearance in WT mice (31). Both Maine et al. and our group studied GC responses and observed no significant differences, suggesting that the humoral response against LCMV was not involved in the enhanced viral clearance observed in PTPN22−/− mice.

Innate immune responses to viruses critically impact the development of adaptive immune responses. Dendritic cells (DCs) play key role in the T cell response against LCMV C113 by producing higher levels of type I IFNs (32). In contrast to what was initially believed, however, type I IFNs exert both beneficial and detrimental effects on antiviral immunity (33). Type I IFNs not only promote innate and adaptive immune activation but are also responsible for the exhaustion of T cells (34, 35). Consequently, blocking IFNA receptor signaling promoted CTL functions and viral clearance (34, 35). IFNα and IFNβ play central but non-redundant role during LCMV C113 infection. However, solely IFNβ blockade could replicate the effect of IFNAR blockade (36). Thus, despite using the same receptor, IFNβ is responsible for promoting viral persistence. Previous studies showed that PTPN22 was needed for efficient activation and TLR-induced type I IFN in myeloid cells following acute infection with LCMV Arm (10). Maine et al. also found that plasmacytoid DCs from PTPN22−/− mice infected with LCMV C113 produced lower levels of type I IFNs (30). Thus, in line with the proposed mechanism by Maine et al., the reduction in IFNβ production in PTPN22−/− mice might contribute to the control of the LCMV C113 infection.

By utilizing the TCR transgenic system specific for the LCMV immunodominant epitope GP33–41 (P14) and adoptive transfer experiments, we previously showed that P14.PTPN22−/− CD8 T cells fail to expand in PTPN22-sufficient hosts following infection with the acute viral strain of LCMV Arm (12). Here, we show that PTPN22 promotes CTL exhaustion in the LCMV C113 system via T cell-extrinsic factors. Collectively, these findings suggest
**FIGURE 7** | The improved CD8 T cell response of protein tyrosine phosphatase non-receptor 22 (PTPN22) deficiency to lymphocytic choriomeningitis virus clone 13 is T cell-extrinsic. (A) Schematic representation of the experimental outline. Lethally irradiated CD45.1+ mice were reconstituted with a 1:1 mixture of CD45.1+CD45.2− PTPN22+/+ and CD45.1+CD45.2− PTPN22−/− bone marrow cells. (B) At 60 days after reconstitution, blood was withdrawn to evaluate the proportion of PTPN22+/+ and PTPN22−/− total, CD3, CD8, and CD4 cells prior to infection. (C,D) Mice were infected as in Figure 1. The proportions of CD3, CD8, and DMR+ cells were determined in the blood 8 days post infection (dpi). (E) Expression levels (geometric mean) of PD-1 were determined on DMR+ PTPN22+/+ and PTPN22−/− CD8 T cells in the blood 8 dpi, with representative histogram overlay for GP33–41-specific cytotoxic lymphocytes shown. (F,G) The proportions of CD3, CD8, and DMR+ cells were determined in the spleen 30 dpi. (H) PD-1 expression levels (geometric mean) were determined on DMR+ PTPN22+/+ and PTPN22−/− CD8 T cells in the spleen 30 dpi with representative histogram overlay shown. (I) The proportions of IFN-γ/TNF CD8 T cells were evaluated by intracellular cytokine staining following stimulation with GP33–41 and NP396–404 peptides [PTPN22+/+ (black circles), PTPN22−/− (white circles)]. (J) The proportions of PTPN22+/+ and PTPN22−/− CD4, Th1 (SLAM+CXCR5+), and Th follicular helper (Tfh) (SLAMloCXCR5+) T cells were determined 30 dpi in the spleen. (K) Frequencies of Th1 and Tfh PTPN22+/+ and PTPN22−/− cells gated on CD4+CD44+ are shown. (L) Representative ICOS and PD-1 expression levels on PTPN22+/+ and PTPN22−/− Th1 and Tfh cells are shown. (M) Splenocytes from chimeric mice were stimulated with GP61–80 peptide and stained for the indicated cytokines. Coexpression of IFN-γ/TNF and IFN-γ/IL-2 was evaluated [PTPN22+/+ (black circles), PTPN22−/− (white circles)]. Data are representative of two independent mixed bone marrow chimera experiments. Number of symbols reflects number of mice per group.
that PTPN22 not only supports CD8 T cell accumulation via T cell-intrinsic mechanisms but also promotes T cell exhaustion by acting on T cell-extrinsic factors. This dual effect of PTPN22 is likely a mechanism that serves to prevent excessive immunopathology and mortality.

Taken together, we report a critical role for PTPN22 in the control of chronic LCMV CJ13 infection. We show that PTPN22 controls the exhaustion phenotype of both CD4 and CD8 T cells and that PTPN22−/− mice have improved CD4 and CD8 T cell responses and increased viral control. Furthermore, we demonstrate that the effects of PTPN22 on CD8 T cell exhaustion phenotype are T cell-extrinsic. Our data suggest that if PTPN22 R620W is a loss-of-function allele, carriers would be more resistant to chronic infections as compared to controls. These studies identify PTPN22 as a promising therapeutic target for chronic infection.

ETHICS STATEMENT

Mice were housed under SPF conditions in compliance with guidelines of the San Raffaele Institutional Animal Care and Use Committee (IACUC approved protocol #677).

REFERENCES

1. Fousteri G, Liossis SN, Battaglia M. Roles of the protein tyrosine phosphatase PTPN22 in immunity and autoimmunity. *Clin Immunol* (2013) 149(3):556–65. doi:10.1016/j.clim.2013.10.006
2. Bottini N, Peterson EJ. Tyrosine phosphatase PTPN22: multifunctional regulator of immune signaling, development, and disease. *Annu Rev Immunol* (2014) 32:83–119. doi:10.1146/annurev-immunol-032713-120249
3. Rawlings DJ, Dai X, Buckner JH. The role of PTPN22 risk variant in the development of autoimmunity: finding common ground between mouse and human. *J Immunol* (2015) 194(7):2977–84. doi:10.4049/jimmunol.1403034
4. Stanford SM, Bottini N, PTPN22: the archetypal non-HLA autoimmunity gene. *Nat Rev Rheumatol* (2014) 10(10):602–11. doi:10.1038/nrrheum.2014.109
5. Rai E, Wéland EK. Genetic predisposition to autoimmunity – what have we learned? *Semin Immunol* (2011) 23(2):67–83. doi:10.1016/j.smim.2011.01.015
6. Hasegawa K, Martin F, Huang G, Tumas D, Diehl L, Chan AC. PEST domain-enriched tyrosine phosphatase (PEP) regulation of effector/memory T cells. *Science* (2004) 303:685–9. doi:10.1126/science.1092138
7. Zhang J, Zahir N, Jiang Q, Miliotis H, Heyraud S, Meng X, et al. The autoimmune disease-associated PTPN22 variant promotes calpain-mediated Lyn/Pep degradation associated with lymphocyte and dendritic cell hyperresponsiveness. *Nat Genet* (2011) 43(9):902–7. doi:10.1038/ng.904
8. Dai X, James RG, Habib T, Singh S, Jackson S, Khin S, et al. A disease-associated PTPN22 variant promotes systemic autoimmunity in murine models. *J Clin Invest* (2013) 123(5):2024–36. doi:10.1172/JCI66963
9. Crabtree JN, He W, Guan W, Flage M, Miller MS, Peterson EJ. Autoimmunity variant PTPN22 C1858T is associated with impaired responses to influenza virus vaccination. *J Infect Dis* (2016) 214:248–57. doi:10.1093/infdis/jiw126
10. Wang Y, Shaked I, Stanford SM, Zhou W, Curtsinger JM, Mikulski Z, et al. The autoimmunity-associated gene PTPN22 potentiates toll-like receptor-driven, type 1 interferon-dependent immunity. *Immunity* (2013) 39(1):111–22. doi:10.1016/j.immuni.2013.06.013
11. Fousteri G, Jofra T, Di Fonte R, Kuka M, Iannacone M, Battaglia M. PTPN22 controls virally-induced autoimmune diabetes by modulating cytotoxic T lymphocyte responses in an epitope-specific manner. *Clin Immunol* (2015) 156(2):98–108. doi:10.1016/j.clim.2014.12.002
12. Jofra T, Di Fonte R, Hutchinson TE, DaStmalchi F, Galvani G, Battaglia M, et al. Protein tyrosine phosphatase PTPN22 has dual roles in promoting pathogen versus homeostatic-driven CD8 T cell responses. *Immunol Cell Biol* (2017) 95(2):121–8. doi:10.1038/icb.2016.92
13. Gallimore A, Glithero A, Godklin A, Tisot AC, Pluckthun A, Elliott T, et al. Induction and exhaustion of lymphocytic choriomeningitis virus-specific cytotoxic T lymphocytes visualized using soluble tetramer major histocompatibility complex class I-peptide complexes. *J Exp Med* (1998) 187(9):1383–93. doi:10.1084/jem.187.9.1383
14. Wherry EJ, Blattman JN, Murali-Krishna K, van der Most R, Ahmed R. Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment. *J Virol* (2003) 77(8):4911–27.
15. Zajac AJ, Blattman JN, Murali-Krishna K, Sourdive DJ, Suresh M, Altman JD, et al. Viral immune evasion due to persistence of activated T cells without effector function. *J Exp Med* (1998) 188(12):2205–13. doi:10.1084/jem.188.12.2205
16. Brooks DG, McGavern DB, Oldstone MB. Reprogramming of antiviral T cells prevents inactivation and restores T cell activity during persistent viral infection. *J Clin Invest* (2006) 116(6):1675–85. doi:10.1172/JCI26856
17. Fousteri G, Dave A, Juntti T, Morin B, McClure M, Von Herrath M. Minimal effect of CD103 expression on the control of a chronic antiviral immune response. *Viral Immunol* (2010) 23(3):285–94. doi:10.1089/vim.2009.0110
18. Virgin HW, Wherry EJ, Ahmed R. Redefining chronic viral infection. *Cell* (2009) 138(1):30–50. doi:10.1016/j.cell.2009.06.036
19. Wherry EJ. T cell exhaustion. *Nat Immunol* (2011) 12(6):492–9.
20. Anikeeva N, Somersalo K, Sims TN, Thomas VK, Dustin ML, Sykulev Y. Distinct role of lymphocyte function-associated antigen-1 in mediating effective cytolytic activity by cytotoxic T lymphocytes. *Proc Natl Acad Sci U S A* (2005) 102(18):6437–42. doi:10.1073/pnas.0502467102
21. Cruz-Guilloty F, Pipkin ME, Djuretic IM, Levanon D, Lotem J, Lichtenheld MG, et al. Runx3 and T-box proteins cooperate to establish the transcriptional program of effector CTLs. *J Exp Med* (2009) 206(1):51–9. doi:10.1084/jem.20081242
22. Raczkowski F, Ritter J, Heesch K, Schumacher V, Guralnik A, Hooker L, et al. The transcription factor interferon regulatory factor 4 is required for the generation of protective effector CD8+ T cells. *Proc Natl Acad Sci U S A* (2013) 110(37):15019–24. doi:10.1073/pnas.1309378110
23. Matloubian M, Concepcion RJ, Ahmed R. CD4+ T cells are required to sustain CD8+ cytotoxic T-cell responses during chronic viral infection. *J Virol* (1994) 68(12):8056–63.

AUTHOR CONTRIBUTIONS

TJ, GG, RF, and BM performed experiments and analyzed data; MK performed experiments, analyzed data, and revised the manuscript; MI and MB discussed data; SS-A discussed data and revised manuscript; GF designed and performed experiments, analyzed data, and wrote the manuscript. All the authors have read and approved the manuscript.

ACKNOWLEDGMENTS

We would like to thank all the past and current members of our groups. We would like to thank Amy Dave for assisting with language editing, and Claudia Cristofani and Carmela G. Maganuco for assisting with the viral titration experiments.

FUNDING

This work was funded by Italian Ministry of Health Young Researchers Award (GR-2011-02348732), JDRF Transition award (1-FAC-2016-144-A-N), and Marie-Curie Integration Grant (276745) to GF.
24. Guidotti LG, Chisari FV. Noncytolytic control of viral infections by the innate and adaptive immune response. *Annu Rev Immunol* (2001) 19:65–91. doi:10.1146/annurev.immunol.19.1.65

25. Fahey LM, Wilson EB, Elsaesser H, Fustinich CD, McGavern DB, Brooks DG. Viral persistence redirects CD4 T cell differentiation toward T follicular helper cells. *J Exp Med* (2011) 208(5):987–99. doi:10.1084/jem.20101773

26. Harker JA, Lewis GM, Mack L, Zuniga EI. Late interleukin-6 escalates T follicular helper cell responses and controls a chronic viral infection. *Science* (2011) 334(6057):825–9. doi:10.1126/science.1208421

27. Maine CJ, Marquardt K, Cheung J, Sherman LA. PTPN22 controls the germinal center by influencing the numbers and activity of T follicular helper cells. *J Immunol* (2014) 192(4):1415–24. doi:10.4049/jimmunol.1302418

28. Maine CJ, Marquardt K, Scatizzi JC, Pollard KM, Kono DH, Sherman LA. The effect of the autoimmunity-associated gene, PTPN22, on a BXSB-derived model of lupus. *Clin Immunol* (2015) 156(1):65–73. doi:10.1016/j.clim.2014.11.003

29. Ng CT, Snell LM, Brooks DG, Oldstone MB. Networking at the level of host immunity: immune cell interactions during persistent viral infections. *Cell Host Microbe* (2013) 13(6):652–64. doi:10.1016/j.chom.2013.05.014

30. Maine CJ, Teijaro JR, Marquardt K, Sherman LA. PTPN22 contributes to exhaustion of T lymphocytes during chronic viral infection. *Proc Natl Acad Sci U S A* (2016) 113(46):E7231–9. doi:10.1073/pnas.1603738113

31. Bergthaler A, Flatz L, Verschoor A, Hegazy AN, Holdener M, Fink K, et al. Impaired antibody response causes persistence of prototypic T cell-contained virus. *PLoS Biol* (2009) 7(4):e1000080. doi:10.1371/journal.pbio.1000080

32. Cervantes-Barragan L, Lewis KL, Firner S, Thiel V, Hugues S, Reith W, et al. Plasmacytoid dendritic cells control T-cell response to chronic viral infection. *Proc Natl Acad Sci U S A* (2012) 109(8):3012–7. doi:10.1073/pnas.1117359109

33. Zuniga EI, Macal M, Lewis GM, Harker JA. Innate and adaptive immune regulation during chronic viral infections. *Annu Rev Virol* (2015) 2(1):573–97. doi:10.1146/annurev-virology-100114-055226

34. Teijaro JR, Ng C, Lee AM, Sullivan BM, Sheehan KC, Welch M, et al. Persistent LCMV infection is controlled by blockade of type I interferon signaling. *Science* (2013) 340(6129):207–11. doi:10.1126/science.1235214

35. Wilson EB, Yamada DH, Elsaesser H, Herskovitz J, Deng J, Cheng G, et al. Blockade of chronic type I interferon signaling to control persistent LCMV infection. *Science* (2013) 340(6129):202–7. doi:10.1126/science.1235208

36. Ng CT, Sullivan BM, Teijaro JR, Lee AM, Welch M, Rice S, et al. Blockade of interferon beta, but not interferon alpha, signaling controls persistent viral infection. *Cell Host Microbe* (2015) 17(5):653–61. doi:10.1016/j.chom.2015.04.005

**Conflict of Interest Statement:** The research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2017 Jofra, Galvani, Kuka, Di Fonte, Mifarrej, Immacaone, Salek-Ardakani, Battaglia and Foustieri. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.